Acorda Therapeutics (Acorda Therapeutics) Effective Interest Rate on Debt % : 16.66% (As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Acorda Therapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Acorda Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $32.2 Mil. Acorda Therapeutics's average total debt for the quarter that ended in Mar. 2024 was $193.4 Mil. Therefore, Acorda Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 16.66%.

Acorda Therapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Acorda Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics Effective Interest Rate on Debt % Chart

Acorda Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

7.37

12.00

13.32

16.60

17.33

Acorda Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															16.58	17.34	16.62	19.52	16.66

Competitive Comparison of Acorda Therapeutics's Effective Interest Rate on Debt %

For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acorda Therapeutics's Effective Interest Rate on Debt % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Acorda Therapeutics's Effective Interest Rate on Debt % falls into.

Acorda Therapeutics Effective Interest Rate on Debt % Calculation

Acorda Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2022 )	+	Total Debt (A: Dec. 2023 ))	/ count )
=	-1 * -31.533	/	( (172.917	+	190.897)	/ 2 )
=	-1 * -31.533	/	181.907
=	17.33 %

where

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	171.372	+	1.545
=	172.917

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	3.166	+	187.731
=	190.897

Acorda Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Dec. 2023 )	+	Total Debt (Q: Mar. 2024 ))	/ count )
=	-1 * -32.228	/	( (190.897	+	195.92)	/ 2 )
=	-1 * -32.228	/	193.4085
=	16.66 %

where

	Total Debt (Q: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	3.166	+	187.731
=	190.897

	Total Debt (Q: Mar. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	2.847	+	193.073
=	195.92

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Acorda Therapeutics (OTCPK:ACORQ) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Acorda Therapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acorda Therapeutics (Acorda Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (OTCPK:ACORQ) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965

Website

https://www.acorda.com

Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.

Executives

Thomas M. Burns	director	2910 SEVENTH STREET, BERKELEY CA 94710
Ron Cohen	officer: CEO and President	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
John Varian	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Michael A Gesser	officer: Chief Financial Officer	420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Neil S. Belloff	officer: General Counsel	11 RADNOR LANE, MAHOPAC NY 10541
Kerry M Clem	officer: Chief Commercial Officer	420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Morales	officer: Interim PAO & PFO	420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Jane Wasman	officer: Exec V Pres, Gen Cnsl & Sec	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella	officer: Exec. VP-Commercial Dvlpmnt	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David Lawrence	officer: Chief Financial Officer	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Capital Management Lp	10 percent owner	152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Lorin Randall	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Burkhard Blank	officer: Chief Medical Officer	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Management, Inc.	10 percent owner	152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Matthew Sirovich	10 percent owner	C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123